Related Experiment Video
Updated: Aug 10, 2026
07:26
Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
Published on: June 29, 2015
Systemic antithrombotic effects of ADAMTS13
Anil K Chauhan1, David G Motto, Colin B Lamb
1CBR Institute for Biomedical Research and Department of Pathology, Harvard Medical School, Boston, MA 02115, USA.
The Journal of Experimental Medicine
|March 15, 2006
Summary
The metalloprotease ADAMTS13 prevents dangerous blood clots by cleaving large von Willebrand factor multimers. This enzyme exhibits natural antithrombotic activity, suggesting its potential use as a therapeutic agent.
Area of Science:
- Hematology
- Vascular Biology
- Protease Function
Background:
- ADAMTS13 (a disintegrin-like and metalloprotease with thrombospondin type I repeats 13) cleaves von Willebrand factor (VWF) multimers.
- ADAMTS13 deficiency causes thrombotic thrombocytopenic purpura (TTP), a condition marked by microvascular thrombi.
- The precise in vivo role of ADAMTS13 in regulating thrombus formation is not fully understood.
Purpose of the Study:
- To investigate the natural antithrombotic activity of ADAMTS13.
- To determine the effect of ADAMTS13 on platelet adhesion and thrombus formation in vivo.
- To explore the potential of recombinant ADAMTS13 as an antithrombotic agent.
Main Methods:
- Intravital microscopy in Adamts13-/- mice to observe spontaneous thrombus formation.
- Administration of an inhibitory ADAMTS13 antibody in wild-type mice.
- Assessment of platelet adhesion and thrombus formation under various conditions, including alphaIIbbeta3 integrin inhibition.
- Evaluation of recombinant ADAMTS13's effects on platelet aggregation and thrombus dissolution.
Main Results:
- Adamts13-/- mice exhibited spontaneous thrombus formation in activated microvenules.
- ADAMTS13 was found to down-regulate platelet adhesion and thrombus formation in injured arterioles.
- Inhibition of ADAMTS13 in wild-type mice led to prolonged platelet adhesion and thrombus formation.
- Recombinant ADAMTS13 reduced platelet adhesion and aggregation and promoted thrombus dissolution.
Conclusions:
- ADAMTS13 possesses significant natural antithrombotic activity.
- The enzyme plays a crucial role in preventing pathological thrombus formation.
- Recombinant ADAMTS13 demonstrates potential as a novel antithrombotic therapeutic agent.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...